EP0507555A1
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Use of rapamycin for treating diabetes
Assignee: Wyeth
•
Filing: 1992-03-31
•
Granted: —
•
Expires: 2012-03-31
Abstract
Abstract This invention concerns the use of rapamycin alone or in combination with insulin in prophylactically preventing the onset, arresting the development, or retarding the progression of insulin dependent diabetes mellitus in a mammal.
Inventors
- 👤 William Lee Baeder
- 👤 Surendra Nath Sehgal
- 👤 Laurel Moore Adams
- 👤 Thomas Joseph Caggiano
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-10-24 22:25
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/70; A61K38/00; A61K38/16; A61K38/17; A61K38/22; A61K38/28; A61P; A61P3/00; A61P3/08; A61P3/10
Claims Analysis
Total Claims: 7
Claim 1
Independent Claim
29 words
Use of rapamycin in the preparation of a medicament for prophylactically preventing the onset; arresting the development or retarding the progression of insulin dependent diabetes mellitus in a mammal.
Claim 2
Dependent Claim
22 words
Use of rapamycin according to Claim 1 in which the medicament is adapted for oral or parenteral administration in unit dosage form.
Claim 3
Dependent Claim
12 words
A pharmaceutical composition comprising rapamycin and insulin and a pharmaceutically acceptable carrier.
Claim 4
Dependent Claim
17 words
A pharmaceutical composition as claimed in Claim 3 wherein unit dosage form for oral or parenteral administration.
Claim 5
Dependent Claim
40 words
A composition or use as claimed in Claim 2 or Claim 4 in which the dose of rapamycin is from 0.1 to 2.5 mg/kg oral or 0.01 to mg/kg parenteral based on the weight of the mammal to be treated.
Claim 6
Dependent Claim
41 words
A composition or use as claimed in Claim 2 or Claim 4 in which the dose of rapamycin is from 0.5 to 18 mg/kg oral or 0.05 to 18 mg/kg parenteral based on the weight of the mammal to be treated.
Claim 7
Dependent Claim
41 words
A composition or used as claimed in Claim 2 or Claim 4 in which the dose of rapamycin is from 1 to 12 mg/kg oral or 0.05 to 12 mg/kg parenteral based on the weight of the mammal to be treated.
References Cited (Backward Citations)
EP0401747A2
Cited
EP0470804A1
Cited
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.